Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

6.3%

4 terminated/withdrawn out of 63 trials

Success Rate

93.2%

+6.7% vs industry average

Late-Stage Pipeline

51%

32 trials in Phase 3/4

Results Transparency

5%

3 of 55 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 3
25(40.3%)
Phase 1
20(32.3%)
Phase 2
8(12.9%)
Phase 4
7(11.3%)
N/A
2(3.2%)
62Total
Phase 3(25)
Phase 1(20)
Phase 2(8)
Phase 4(7)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (63)

Showing 20 of 63 trials
NCT05445895Phase 4Completed

A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke

Role: lead

NCT06989697Phase 3Recruiting

Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes

Role: collaborator

NCT05906199Phase 4Completed

A Study to Compare the Effects of Improving the Carotid Artery Intima Media Thickness and Changing Lipid Levels by Cilostazol/Ginkgo Leaf Extract and Aspirin in Diabetic Peripheral Angiopathy.

Role: lead

NCT04754451Phase 4Completed

The Effect of Lidocaine Patch for Postoperative Pain

Role: collaborator

NCT05930080Phase 3Completed

Efficacy and Safety of SKCPT in Patients With Knee Osteoarthritis: Phase III Clinical Trial

Role: lead

NCT04821687Phase 4Completed

A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD

Role: lead

NCT05400395Phase 4Unknown

Clinical Trial for GNX80 in Intermittent Claudication

Role: lead

NCT05453786Phase 1Completed

A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers

Role: lead

NCT05236998Phase 1Completed

A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers

Role: lead

NCT04718649Not ApplicableUnknown

Effectiveness and Safety of Celecoxib (Celebrex 200 mg) Combined With Joins in the Treatment of Degenerative Knee Osteoarthritis: a Randomized Controlled Trial

Role: collaborator

NCT04401137Phase 1Completed

The Evaluation of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of QDX in Healthy Korean Male Subjects

Role: lead

NCT02467842Phase 3Completed

Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects

Role: lead

NCT02645032Phase 1Completed

Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine

Role: collaborator

NCT02927444Phase 3Completed

Immunogenicity and Safety Study of NBP606 in Healthy Toddlers

Role: lead

NCT02201030Phase 3Completed

Immunogenicity and Safety Study of NBP606 in Healthy Infants

Role: lead

NCT03484871Withdrawn

Resting-state Functional Connectivity Changes During Migraine Treatment

Role: collaborator

NCT03318276Phase 3Completed

Clinical Trial to Evaluate Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease

Role: lead

NCT02159976Not ApplicableCompleted

Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea

Role: collaborator

NCT03893669Phase 1Completed

Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults

Role: lead

NCT03826719Phase 1Completed

Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers

Role: lead